SB 1728 / HB 1429 — what the Medical Spa Prescription Drug Oversight Act meant, why it died, and what to expect in 2027.

Why this bill existed

The 2024–2025 Florida med-spa landscape produced a string of news cycles that put med-spa regulation on the legislature's agenda. The high-profile DeSoto Med Spa case in Sarasota — a wrongful-death lawsuit tied to a procedure performed under a "paper" medical director arrangement — was widely reported. AHCA inspections in 2025 surfaced a pattern of med spas operating without the HCC license or exemption letter the Health Care Clinic Act requires. National coverage of botulinum toxin counterfeiting, "underground Botox," and outpatient adverse events landed in Florida media. By the fall of 2025, several Florida medical and pharmacy groups were drafting a model bill.

The bill that emerged — SB 1728 in the Senate, HB 1429 in the House — was, in its drafters' words, a "consolidation" of existing law plus a few new requirements. The consolidation was real: Florida med spas already answer to § 458 (Medical Practice Act), § 400 Part X (Health Care Clinic Act), § 893 (Drug Abuse Prevention and Control), Chapter 464 (Nursing), § 456.47 (telehealth), and Board of Medicine rules. SB 1728 would have created a single med-spa-specific licensure track and a uniform reporting regime.

What the bill would have done

The bill, as filed, would have:

• Created a new licensure category for medical spas with the Florida Department of Health, separate from but intersecting with the existing AHCA Health Care Clinic licensure.
• Brought med spas under Florida Board of Pharmacy oversight for prescription drug handling — particularly Schedule III injectables (botulinum toxin), dermal fillers when prescription-only, and weight-loss compounds dispensed at the clinic.
• Required documentation of drug source — a written record of the wholesaler, distributor, or compounding pharmacy from which each dose was obtained, with lot numbers and acquisition dates.
• Mandated 5-day adverse event reporting — a clinic that observed or learned of an adverse event tied to a procedure would have been required to report it to a designated authority within 5 days, on a prescribed form.
• Tightened the supervisory framework — adding statutory language to the existing § 458.348 framework with specific GFE timing rules and documentation standards for supervisor-mid-level relationships in the med-spa setting.
• Added penalties — civil penalties layered on the existing § 400.9935 felony for unlicensed clinic operation.
• Provided enforcement authority for a coordinated AHCA / Board of Medicine / Board of Pharmacy investigation track on med-spa-specific complaints.

The legislative timeline

• Late 2025 — Working drafts circulated by sponsoring members and industry stakeholders. Florida Medical Association, Florida Society of Plastic Surgeons, and several patient-safety groups offered position letters.
• January 2026 — SB 1728 filed in the Senate by Senator Joe Gruters; HB 1429 filed as a companion in the House.
• February 2026 — Senate Health Policy Committee held an information-only hearing on SB 1728. Several med-spa owners and industry trade associations testified.
• Early March 2026 — Substitute amendments offered in both chambers tightened the adverse event reporting provisions and eased the proposed Board of Pharmacy involvement after industry objections.
• March 13, 2026 — HB 1429 failed to advance out of the House Health Professions & Programs Subcommittee before the subcommittee's effective deadline. With no House vehicle, SB 1728 stalled on the Senate side. The 2026 session adjourned with both bills dead.
• April–May 2026 — Sponsors and stakeholder groups began circulating a 2027 draft. The substantive direction is similar; the political vehicle is unsettled.

Why it died

Bills of this scope rarely fail for one reason. The retrospective on SB 1728 / HB 1429 surfaces three contributing factors:

1. Industry pushback on the Board of Pharmacy clause. Placing med spas under Pharmacy Act oversight in addition to Medical Practice Act and Health Care Clinic Act oversight was, for many medical directors and clinic owners, a regulatory triplication they could not stomach. The Florida Society of Plastic Surgeons and several allied groups raised objections about practitioner-to-pharmacy hand-offs.
2. Disagreement on the licensure category. The bill created a "medical spa" definition that several stakeholders believed was either too broad (sweeping in physician-owned practices that the existing AHCA exemption already excluded) or too narrow (allowing high-risk operators to escape it through arrangement).
3. Calendar pressure. The 2026 session compressed the window for amendments after the February substitute language landed. The House subcommittee deadline arrived before negotiations resolved.

None of these factors are resolved in any structural sense. They are negotiation items for a 2027 vehicle.

What's already enforceable, mapped to what SB 1728 would have done

Adverse event documentation

SB 1728 would have introduced a 5-day reporting form. Today, adverse events are reportable under multiple existing channels: the Board of Medicine takes mandatory practitioner self-reports under § 458.351 and § 458.331 in defined scenarios, AHCA expects HCC clinics to maintain incident logs as part of their QA program, and § 766.110 imposes risk management obligations on health care providers. There is no single five-day form yet, but a clinic that fails to log and respond to an adverse event in 2026 is exposed under several existing frameworks. The defensible practice is a written incident-tracking log, with practitioner sign-off and a record of any external reporting decisions.

Drug source records

SB 1728 would have made drug source records statutorily explicit. Today, Florida pharmacy and controlled substance rules already require that prescription drugs be obtained from a registered wholesaler or pharmacy, that botulinum toxin (Schedule III) be tracked to dose level, that compounded products from a 503A or 503B pharmacy carry the source documentation, and that the FDA's Drug Supply Chain Security Act (DSCSA) tracking apply for prescription product. Sloppy or missing source records are already a cited deficiency in AHCA inspections. ProofOps stores the purchase invoice, lot number, and acquisition date for each Schedule III dose received.

Supervisory protocols and GFEs

SB 1728 would have written specific GFE timing into statute. Today, GFE standards live in the standard of care, § 458.348 / § 458.347 supervisory protocols, § 893.03 prescribing rules, and Board of Medicine rule 64B8-9.009. They are already strict — see our Florida GFE explainer.

Clinic licensure

SB 1728 would have created a med-spa-specific license. Today, med spas need an AHCA HCC license (or a written exemption determination) under § 400.9905 and Rule 59A-33. See our AHCA HCC explainer.

The "paper MD" problem

SB 1728 would have tightened supervisory geography statutorily. Today, § 458.348(1)(f) — the 25-mile rule and contiguous-county alternative — already does most of that work. See our § 458.348 explainer.

What 2027 likely looks like

Predicting Florida legislation is humbling. The most credible scenarios for the 2027 session:

• A near-replay of SB 1728 with the Board of Pharmacy clause softened and a narrower medical-spa definition — the "consolidation" framing remains attractive to multiple caucuses.
• A registration-only bill that creates a med-spa registry with annual reporting but stops short of a full licensure regime, which would be substantially less politically contentious.
• A package approach that splits the original SB 1728 into two or three smaller bills (adverse event reporting; drug source documentation; supervisory tightening), each easier to pass standalone.
• An incident-driven acceleration if a high-profile adverse event in 2026 lands with sufficient force in Tallahassee to override the procedural drag.

The single highest-confidence prediction: whatever bill emerges in 2027 will demand documentation that already exists in fragments today. Clinics that have organized those fragments into one file in 2026 will adopt the new statute as paperwork; clinics that haven't will scramble.

What an owner should do today

1. Pull the AHCA HCC license or exemption letter into the file. If neither exists, get one or the other on file in the next 60 days.
2. Re-execute the supervisory protocol with the current medical director, dated and signed, addressing the procedures actually performed.
3. Audit your GFE record for the past 90 days. How many charts have a substantive GFE? How many are template-only?
4. Build an incident log if you don't have one. Front-load the format and escalation chain before you need them.
5. Document drug source for every Schedule III dose received. Wholesaler invoice, lot number, acquisition date, on file with the inventory record.
6. Consolidate it. The fragmented file is the trap. One bookmarked PDF a month is the way out.

These are the steps a clinic would have to take if SB 1728 had passed. They are also the steps that protect a clinic if SB 1728's successor passes in 2027 — or if AHCA opens an inspection tomorrow.

Frequently asked questions

Is there any version of SB 1728 still alive in 2026?

No. Both SB 1728 and HB 1429 are dead for the 2026 session. No procedural revival mechanism applies. The 2027 session is the next opportunity.

If I'm not in trouble today, do I still need to organize for SB 1728's reincarnation?

The framing is backward. The documentation SB 1728 named is what protects you today, under existing Florida law. Whether the 2027 bill passes is a secondary question — the underlying expectations are already binding.

Did the Florida Medical Association support SB 1728?

The Florida Medical Association's position on the bill evolved during the session. The organization publicly supported the underlying patient-safety objectives but raised concerns about the Board of Pharmacy oversight clause and the breadth of the medical-spa definition. Other physician societies were similarly mixed.

Was Senator Gruters the only sponsor?

Senator Joe Gruters was the lead Senate sponsor. The bill picked up co-sponsors during the session. HB 1429 had its own House sponsor team. Sponsorship for a 2027 vehicle is unsettled.

Where can I read the bill text?

SB 1728 and HB 1429 bill text, amendment history, and committee staff analyses are publicly available on flsenate.gov and myfloridahouse.gov. Search by bill number for the 2026 regular session. Staff analyses provide a useful committee-level read of what the bill actually changed, section by section.

What does ProofOps do for clinics that want to be ready for 2027?

The same thing we do for clinics that want to pass an AHCA inspection today. We organize the documentation, run the agents that close gaps, and produce a monthly inspection-ready PDF. The statutory citations on each section update with the law; the underlying records are the records.

How ProofOps Medical helps

ProofOps was built to surface, collect, and organize the documentation Florida med spas already owe under existing law. If SB 1728's successor passes in 2027, the new statute's checklist will map onto the file ProofOps maintains today — section by section. If it doesn't, the same file passes an AHCA inspection, defends a § 456.073 complaint, and supports an insurance renewal.

Get a free audit — see your specific FL gaps before you commit. Or watch the 6-minute demo.

This page is informational. It is not legal advice. SB 1728 and HB 1429 bill texts and committee histories are public records on flsenate.gov and myfloridahouse.gov. For interpretation specific to your clinic, consult your Florida healthcare attorney. Source: Florida Senate and House bill-tracking systems, sponsor releases, and committee staff analyses as of May 2026.